We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Living With is a health technology company offering a pocket-friendly and simple patient management application that allows medical professionals treat and track patients remotely. The app aims to revolutionise the way doctors and hospitals access digital tools to treat patients while collecting data for medical device and pharma companies. The company owns Squeezy (a popular paid medical app in the UK) and already has five products in 17 NHS Trusts. Living With also has a contract with one of the world’s greatest medical device companies. Living With will use the proceeds to give 5 data (drug/device) and 50 access customers (clinic/doctor), become HIPAA compliant for the US and to quicken sales and marketing.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £200,000
MedicSpot is a healthcare company that is aiming to revolutionise healthcare delivery by combining the advantages of online and offline care. The company provides patients at designated hospitals with diagnostic tools like a stethoscope, oximeter, blood pressure monitor and thermometer which, in turn, is connected to the MedicSpot network. Onboard General Physicians (GPs) engage in live sessions with patients, guide them on how to use the tools, and perform a variety of diagnoses like listening to a patient’s heart and lungs, looking down their throat and into their ears, taking their blood pressure and oxygen readings, and measuring their body temperature. The company is also expanding into another subsidiary, Arc Health, which it claims will perform the aforementioned tasks with more efficiency and accuracy. The company will use the investment to increase the number of Medicspot clinics to 1,000, gain further NHS market share, launch a corporate business model and allow international pilots to take place.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £1,048,396
Carocell Bio is an early-stage Research and Design (R&D) company aiming to develop nanoparticle-based, novel peptide anti-inflammatories to treat atopic dermatitis/eczema (AD) and other serious inflammatory diseases. It argues that millions of people continue to be affected by debilitating skin ailments, which in turn, escalates the development of new pharmaceutical drugs. The company asserts that the anti-inflammatory therapeutics market will reach US$122.6 billion by 2025 from US$95.9 billion in 2019. The company aims to be a major contender in this market. Carocell Bio has also been awarded an Innovate UK grant of £390,874. The company is seeking £1 million in equity investment over the next 12 months to show that their compounds work in human tissue biopsies of several inflammatory diseases.

Pitch Rated

45%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
Nikalyte is a specialist in nanoparticles research and development (R&D) as well as commercialisation in various application areas such as cell binding, cell separation, drug delivery, catalysis, nano-photonics, and electrochemistry. The company is developing a nanoparticle generator, which will enable researchers to produce nanoparticles of almost any metal or alloy on almost any substrate via a user-friendly interface. Nikalyte is offering free nanoparticle samples to researchers investigating antiviral materials, such as Copper and Silver, towards developing a vaccine for Covid-19. The company also offers a consultancy service that provides advice on nanoparticle applications and ultra-high vacuum systems. The company aims to use the investment to scale its business.

Pitch Rated

37%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
AgPlus has created a diagnostic platform for detecting human diseases and delivering laboratory instrument results instantly, whilst keeping in mind the business requirements and unmet requirements. The company works in collaboration with leading diagnostics companies to improve and share products quickly and globally. It aims is to become known as a leader in Point of Care diagnosis.
days to go: Expired investment: £65,004
Ablatus Therapeutics is a MedTech company developing a one-of-a-kind tissue ablation platform known as Bimodal Electric Tissue Ablation (BETA). This technology has been designed to overcome the limitations of existing products by offering ablation solutions in oncology (tumours) as well as non-oncology targets. With the proceeds, the company will finish the final elements of engineering of the generator and probe. It will also deliver formal safety test data that is a prerequisite for subsequent clinical trials.
days to go: Expired investment: Withheld
Antev Limited (Antev) is a clinical-stage biopharmaceutical firm which focuses on the evolution of a drug used for prostate cancer, Teverelix TFA. The company is working on growing its copyright protection and is currently developing phase IIb clinical plans for prostate cancer. Antev is a pre-revenue company that aims at increasing its shareholder value by progressing the development of teverelix TFA towards registration whose approval is anticipated from 2023 onwards. The proceeds will be used for production, IP development, working capital and to develop a phase IIb repeat dosing clinical trial in prostate cancer.
days to go: Expired investment: Withheld
INSPHERE uses image sensors and Artificial Intelligence (AI) to guide and correct robot positioning during the manufacturing process, ensuring right-first-time production. The company argues that industrial robots are not completely accurate and can experience unplanned downtime that can cost up to £10,000 per minute. INSPHERE asserts that its solution allows factory operators to operate safely with less downtime, and with multiple robot and human operators. The company has developed three products since 2013 which have received recognition in the aerospace and industrial automation sectors. INSPHERE is now launching IONA, a network of sensors that can be permanently deployed in a manufacturing environment to monitor and control industrial robots. IONA, the company points out, uses both hardware and software to correct errors taking into account the robot and its relationship to the workpiece. INSPHERE will use the investment to diversify the reach of IONA across markets.
days to go: Expired investment: £1,149,999
Jobhawk is the UK’s first digital marketplace for construction labour. They aim to make it possible for sub-contractors to get self-employed labour instantly for their projects. They have developed an app that matches the UK's leading subcontractors with bricklayers, carpenters and other tradesmen, with less effort for everyone involved.
days to go: Expired investment: £728,573
Lightpoint Medical is a technology company that is a pioneer in developing and marketing precision-guided cancer surgery. Surgeons aren't able to see if the cancerous tissue has been removed in its entirety or not during a surgery. To better this situation, the company has developed an imaging technology based on PET radiopharmaceuticals, more precisely, Cerenkov Luminescence Imaging (CLI), which helps surgeons to detect cancer in a real-time during surgery. The company's first product has received marketing authorisation, i.e., the CE (European Conformity) Mark. A second product, a laparoscopic device for prostate cancer is in development. A non-clinical device has also been released. For its efforts, Lightpoint Medical won the 'Best in Show' Award at the 2014 MedTech Investing Europe Conference. The company aims to utilise the investment to scale its business.
days to go: Expired investment: Withheld
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph